Immutep (NASDAQ: IMMP) receives Nasdaq notice on sub-US$1.00 bid price
Rhea-AI Filing Summary
Immutep Limited received a Nasdaq notice that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00 per share, after trading below that level for 30 consecutive business days ended 24 April 2026. The notice has no immediate effect on Nasdaq listing or trading. Immutep has 180 calendar days, until 26 October 2026, to regain compliance by having its closing bid at or above US$1.00 for at least ten consecutive business days. The company plans to monitor its share price and consider options to restore compliance, while its ordinary shares continue to trade on the ASX.
Positive
- None.
Negative
- Nasdaq bid-price deficiency: Immutep’s American Depositary Shares failed to meet Nasdaq’s minimum bid price of US$1.00 for 30 consecutive business days, leading to a formal non-compliance notice and a defined deadline to regain compliance.
Insights
Nasdaq bid-price noncompliance creates listing risk but no immediate trading impact.
Immutep has fallen below Nasdaq’s US$1.00 minimum bid requirement for 30 consecutive business days, triggering a formal deficiency notice under Nasdaq Listing Rule 5450(a)(1). The company’s American Depositary Shares remain listed and tradable on Nasdaq for now.
Nasdaq has granted a 180-day compliance window, to 26 October 2026, during which a closing bid at or above US$1.00 for at least ten consecutive business days would restore compliance. If this does not occur, Nasdaq could take further actions, though these are not detailed here.
Immutep states it will monitor its Nasdaq bid price and consider available options. Its ordinary shares continue trading on the ASX, so investors effectively retain a dual-listing structure while the company works through this bid-price issue.
Key Figures
Key Terms
Nasdaq Listing Rule 5450(a)(1) regulatory
minimum bid price requirement regulatory
continuous disclosure obligations regulatory
Lymphocyte Activation Gene-3 (LAG-3) medical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date as April 30, 2026
Commission File Number 001-35428
IMMUTEP LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrant’s Name)
Level 32, Australia Square
264 George Street, Sydney
NSW 2000, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
EXHIBIT INDEX
| Exhibit |
Description of Exhibit | |
| 99.1 |
Immutep Receives Nasdaq Notice of Bid Price Deficiency | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: April 30, 2026
| IMMUTEP LIMITED | ||
| By: | /s/ Marc Voigt | |
| Name: | Marc Voigt | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
Immutep Receives Nasdaq Notice of Bid Price Deficiency
SYDNEY, AUSTRALIA – April 30, 2026 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock Market LLC (Nasdaq) regarding non-compliance with the Nasdaq minimum bid price requirement.
Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share. Based on the closing bid price of the Company’s American Depositary Shares for the 30 consecutive business days ended 24 April 2026, the Company does not currently meet this requirement.
The notification has no immediate effect on the listing or trading of the Company’s American Depositary Shares on Nasdaq. In accordance with Nasdaq rules, the Company has been provided an initial compliance period of 180 calendar days, expiring on 26 October 2026, to regain compliance.
If at any time during the compliance period the closing bid price of the Company’s American Depositary Shares is at least US$1.00 per share for a minimum of ten consecutive business days (or such longer period as Nasdaq may require), Nasdaq will notify the Company that compliance has been regained.
The Company intends to monitor the bid price of its American Depositary Shares and will consider available options to regain compliance within the prescribed timeframe. There can be no assurance that the Company will regain compliance during this period.
The Company remains listed on the ASX, and this notification does not affect the trading of its ordinary shares on ASX.
Immutep will keep the market informed of any material developments in accordance with its continuous disclosure obligations.
About Immutep
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
Immutep Limited, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia
ABN: 90 009 237 889
U.S. Investors/Media:
Matthew Beck, astr partners
Ph: +1 (917) 415-1750; matthew.beck@astrpartners.com
Immutep Limited, Level 32, Australia Square, 264 George Street, Sydney NSW 2000, Australia
ABN: 90 009 237 889